Topos Bio is an AI-native drug discovery company based in San Francisco that develops computational methods for intrinsically disordered proteins (IDPs), a target class the company notes accounts for roughly 30-40% of the human proteome. Its work is directed at diseases including neurodegeneration, such as Alzheimer's disease, and aggressive cancers. The company recently emerged from stealth mode and has raised $10.5 million in seed funding.
The company's technical stack spans protein conformational ensemble modelling, generative AI, computational chemistry and proteome-scale mapping, combined with high-throughput experimental validation. Its models include Topos-1, an all-atom generative model that produces realistic conformational ensembles for disordered proteins; Topos-2, which maps conformational ensembles across the human proteome through the company's BioScape technology; and Topos-Bind, which models small-molecule interactions with protein ensembles and is described by the company as the first generative model to produce ensembles of disordered proteins bound to small molecules.
Topos Bio pursues collaborative partnerships ranging from early discovery to co-development, and is a member of pharmaceutical initiatives including Lilly's TuneLab platform. The company frames its focus as targeting previously considered "undruggable" proteins and other frontier scientific problems in drug discovery.
